DIECI, Maria Vittoria
DIECI, Maria Vittoria
Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
2010-01-01 Guarneri, Valentina; Barbieri, Elena; Dieci, Mv; Piacentini, Federico; Conte, Pierfranco
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
2019-01-01 Dieci, Mv; Conte, P; Bisagni, G; Brandes, Aa; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S; D'Amico, R; Guarneri, V.
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts
2011-01-01 Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, G; Bettelli, Stefania Raffaella; Conte, Pierfranco; Guarneri, Valentina
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management
2008-01-01 Guarneri, Valentina; Giovannelli, Simona; Ficarra, G; Bettelli, Stefania Raffaella; Maiorana, Antonino; Piacentini, Federico; Barbieri, Elena; Dieci, Maria Vittoria; D'Amico, Roberto; Jovic, Gordana; Conte, Pierfranco
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS
2008-01-01 Guarneri, V.; Giovannelli, S.; Ficarra, G.; Bettelli, S.; Piacentini, F.; Barbieri, E.; Dieci, Mv.; Jovic, G.; Conte, Pf.
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis
2012-01-01 Dieci, Maria Vittoria; Barbieri, Elena; Piacentini, Federico; Ficarra, G; Bettelli, Stefania Raffaella; Dominici, Massimo; Conte, Pierfranco; Guarneri, Valentina
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y)
2017-01-01 Dieci, M. V.; Frassoldati, A.; Generali, D.; Bisagni, G.; Piacentini, F.; Cavanna, L.; Cagossi, K.; Puglisi, F.; Michelotti, A.; Berardi, R.; Banna, G.; Goubar, A.; Ficarra, G.; Griguolo, G.; Conte, P.; Guarneri, V.
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial
2021-01-01 Guarneri, V.; Giorgi, C. A.; Cinieri, S.; Bengala, C.; Mariani, G.; Bisagni, G.; Frassoldati, A.; Zamagni, C.; De Rossi, C.; Amoroso, V.; Andreetta, C.; Ferro, A.; Zambelli, A.; Gori, S.; Garrone, O.; Dieci, M. V.; Orlando, L.; Pastina, I.; Beninato, T.; Moretti, G.; Genovesi, E.; Cinefra, M.; Vicini, R.; Magni, G.; De Salvo, G. L.; Conte, P.
Immune characterization of breast cancer metastases: prognostic implications.
2018-01-01 Dieci, Mv; Tsvetkova, V; Orvieto, E; Piacentini, F; Ficarra, G; Griguolo, G; Miglietta, F; Giarratano, T; Omarini, C; Bonaguro, S; Cappellesso, R; Aliberti, C; Vernaci, G; Giorgi, Ca; Faggioni, G; Tasca, G; Conte, P; Guarneri, V.
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer.
2021-01-01 Griguolo, G; Dieci, Mv; Paré, L; Miglietta, F; Generali, Dg; Frassoldati, A; Cavanna, L; Bisagni, G; Piacentini, F; Tagliafico, E; Cagossi, K; Ficarra, G; Prat, A; Conte, P; Guarneri, V.
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
2016-01-01 Musolino, A; Naldi, N; Dieci, Maria Vittoria; Zanoni, Daniele; Rimanti, Anita; Boggiani, D; Sgargi, P; Generali, Dg; Piacentini, Federico; Ambroggi, M; Cagossi, K; Gianni, L; Sarti, S; Bisagni, G; Ardizzoni, Andrea; Conte, Pf; Guarneri, Valentina
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY
2010-01-01 Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, Guido; Conte, Pierfranco; Guarneri, Valentina
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy
2010-01-01 Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, G; Conte, Pierfranco; Guarneri, Valentina
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
2013-01-01 Guarneri, Valentina; Dieci, Maria Vittoria; Barbieri, E; Piacentini, Federico; Omarini, Claudia; Ficarra, G; Bettelli, Stefania Raffaella; Conte, Pierfranco
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer
2011-01-01 Guarneri, Valentina; Pecchi, A; Piacentini, Federico; Barbieri, Elena; Dieci, Mv; Ficarra, G; Tazzioli, Giovanni; Frassoldati, A; Battista, R; Canossi, Barbara; Mauri, C; D'Amico, Roberto; Conte, Pierfranco; Torricelli, Pietro
MANAGEMENT OF ADVANCED BREAST CANCER: HOW TO INTEGRATE SCIENTIFIC DATA AND CLINICAL JUDGMENT
2012-01-01 Conte, P.; Dieci, M. V.; Piacentini, F.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
2020-01-01 Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T; Dieci, Mv; Chic, N; González-Farré, B; Frassoldati, A; Sanfeliu, E; Cejalvo, Jm; Muñoz, M; Bisagni, G; Brasó-Maristany, F; Urso, L; Vidal, M; Brandes, Aa; Adamo, B; Musolino, A; Miglietta, F; Conte, B; Oliveira, M; Saura, C; Pernas, S; Alarcón, J; Llombart-Cussac, A; Cortés, J; Manso, L; López, R; Ciruelos, E; Schettini, F; Villagrasa, P; Carey, La; Perou, Cm; Piacentini, F; D'Amico, R; Tagliafico, E; Parker, Js; Conte, P
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype.
2020-01-01 Guarneri, Valentina; Dieci, Maria Vittoria; Bisagni, Giancarlo; Brandes, Alba A.; Frassoldati, Antonio; Cavanna, Luigi; Musolino7, Antonino; 8, ; Giotta9, Francesco; Rimanti10, Anita; Garrone11, Ornella; Bertone, Elena; Cagossi, Katia; Nanni, Oriana; Piacentini, Federico; Orvieto, Enrico; Griguolo, Gaia; Curtarello, Matteo; Urso, Loredana; Pare, Laia; Chic, Nuria; D'Amico, Roberto; Prat and Pierfranco Conte, Aleix
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY.
2020-01-01 Guarneri, Valentina; Dieci, Maria Vittoria; Bisagni, Giancarlo; Brandes, Alba A.; Frassoldati, Antonio; Cavanna, Luigi; Musolino, Antonino; Giotta, Francesco; Rimanti, Anita; Garrone, Ornella; Elenabertone, ; Cagossi, Katia; Nanni, Oriana; Piacentini, Federico; Orvieto, Enrico; Curtarello, Matteo; Chic, Nuria; D'Amico, Roberto; Prat, Aleix; Conte, Pierfranco
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis.
2012-01-01 Dieci, Maria Vittoria; Barbieri, Elena; Bettelli, Stefania Raffaella; Piacentini, Federico; Omarini, Claudia; Ficarra, G; Balduzzi, Sara; Dominici, Massimo; Conte, Pierfranco; Guarneri, Valentina
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer | 1-gen-2010 | Guarneri, Valentina; Barbieri, Elena; Dieci, Mv; Piacentini, Federico; Conte, Pierfranco | |
| Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. | 1-gen-2019 | Dieci, Mv; Conte, P; Bisagni, G; Brandes, Aa; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S; D'Amico, R; Guarneri, V. | |
| Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts | 1-gen-2011 | Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, G; Bettelli, Stefania Raffaella; Conte, Pierfranco; Guarneri, Valentina | |
| Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management | 1-gen-2008 | Guarneri, Valentina; Giovannelli, Simona; Ficarra, G; Bettelli, Stefania Raffaella; Maiorana, Antonino; Piacentini, Federico; Barbieri, Elena; Dieci, Maria Vittoria; D'Amico, Roberto; Jovic, Gordana; Conte, Pierfranco | |
| COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS | 1-gen-2008 | Guarneri, V.; Giovannelli, S.; Ficarra, G.; Bettelli, S.; Piacentini, F.; Barbieri, E.; Dieci, Mv.; Jovic, G.; Conte, Pf. | |
| Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis | 1-gen-2012 | Dieci, Maria Vittoria; Barbieri, Elena; Piacentini, Federico; Ficarra, G; Bettelli, Stefania Raffaella; Dominici, Massimo; Conte, Pierfranco; Guarneri, Valentina | |
| Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) | 1-gen-2017 | Dieci, M. V.; Frassoldati, A.; Generali, D.; Bisagni, G.; Piacentini, F.; Cavanna, L.; Cagossi, K.; Puglisi, F.; Michelotti, A.; Berardi, R.; Banna, G.; Goubar, A.; Ficarra, G.; Griguolo, G.; Conte, P.; Guarneri, V. | |
| Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial | 1-gen-2021 | Guarneri, V.; Giorgi, C. A.; Cinieri, S.; Bengala, C.; Mariani, G.; Bisagni, G.; Frassoldati, A.; Zamagni, C.; De Rossi, C.; Amoroso, V.; Andreetta, C.; Ferro, A.; Zambelli, A.; Gori, S.; Garrone, O.; Dieci, M. V.; Orlando, L.; Pastina, I.; Beninato, T.; Moretti, G.; Genovesi, E.; Cinefra, M.; Vicini, R.; Magni, G.; De Salvo, G. L.; Conte, P. | |
| Immune characterization of breast cancer metastases: prognostic implications. | 1-gen-2018 | Dieci, Mv; Tsvetkova, V; Orvieto, E; Piacentini, F; Ficarra, G; Griguolo, G; Miglietta, F; Giarratano, T; Omarini, C; Bonaguro, S; Cappellesso, R; Aliberti, C; Vernaci, G; Giorgi, Ca; Faggioni, G; Tasca, G; Conte, P; Guarneri, V. | |
| Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. | 1-gen-2021 | Griguolo, G; Dieci, Mv; Paré, L; Miglietta, F; Generali, Dg; Frassoldati, A; Cavanna, L; Bisagni, G; Piacentini, F; Tagliafico, E; Cagossi, K; Ficarra, G; Prat, A; Conte, P; Guarneri, V. | |
| Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer | 1-gen-2016 | Musolino, A; Naldi, N; Dieci, Maria Vittoria; Zanoni, Daniele; Rimanti, Anita; Boggiani, D; Sgargi, P; Generali, Dg; Piacentini, Federico; Ambroggi, M; Cagossi, K; Gianni, L; Sarti, S; Bisagni, G; Ardizzoni, Andrea; Conte, Pf; Guarneri, Valentina | |
| KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY | 1-gen-2010 | Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, Guido; Conte, Pierfranco; Guarneri, Valentina | |
| Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy | 1-gen-2010 | Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, G; Conte, Pierfranco; Guarneri, Valentina | |
| Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients | 1-gen-2013 | Guarneri, Valentina; Dieci, Maria Vittoria; Barbieri, E; Piacentini, Federico; Omarini, Claudia; Ficarra, G; Bettelli, Stefania Raffaella; Conte, Pierfranco | |
| Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer | 1-gen-2011 | Guarneri, Valentina; Pecchi, A; Piacentini, Federico; Barbieri, Elena; Dieci, Mv; Ficarra, G; Tazzioli, Giovanni; Frassoldati, A; Battista, R; Canossi, Barbara; Mauri, C; D'Amico, Roberto; Conte, Pierfranco; Torricelli, Pietro | |
| MANAGEMENT OF ADVANCED BREAST CANCER: HOW TO INTEGRATE SCIENTIFIC DATA AND CLINICAL JUDGMENT | 1-gen-2012 | Conte, P.; Dieci, M. V.; Piacentini, F. | |
| A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation | 1-gen-2020 | Prat, A; Guarneri, V; Paré, L; Griguolo, G; Pascual, T; Dieci, Mv; Chic, N; González-Farré, B; Frassoldati, A; Sanfeliu, E; Cejalvo, Jm; Muñoz, M; Bisagni, G; Brasó-Maristany, F; Urso, L; Vidal, M; Brandes, Aa; Adamo, B; Musolino, A; Miglietta, F; Conte, B; Oliveira, M; Saura, C; Pernas, S; Alarcón, J; Llombart-Cussac, A; Cortés, J; Manso, L; López, R; Ciruelos, E; Schettini, F; Villagrasa, P; Carey, La; Perou, Cm; Piacentini, F; D'Amico, R; Tagliafico, E; Parker, Js; Conte, P | |
| PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. | 1-gen-2020 | Guarneri, Valentina; Dieci, Maria Vittoria; Bisagni, Giancarlo; Brandes, Alba A.; Frassoldati, Antonio; Cavanna, Luigi; Musolino7, Antonino; 8, ; Giotta9, Francesco; Rimanti10, Anita; Garrone11, Ornella; Bertone, Elena; Cagossi, Katia; Nanni, Oriana; Piacentini, Federico; Orvieto, Enrico; Griguolo, Gaia; Curtarello, Matteo; Urso, Loredana; Pare, Laia; Chic, Nuria; D'Amico, Roberto; Prat and Pierfranco Conte, Aleix | |
| PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY. | 1-gen-2020 | Guarneri, Valentina; Dieci, Maria Vittoria; Bisagni, Giancarlo; Brandes, Alba A.; Frassoldati, Antonio; Cavanna, Luigi; Musolino, Antonino; Giotta, Francesco; Rimanti, Anita; Garrone, Ornella; Elenabertone, ; Cagossi, Katia; Nanni, Oriana; Piacentini, Federico; Orvieto, Enrico; Curtarello, Matteo; Chic, Nuria; D'Amico, Roberto; Prat, Aleix; Conte, Pierfranco | |
| Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. | 1-gen-2012 | Dieci, Maria Vittoria; Barbieri, Elena; Bettelli, Stefania Raffaella; Piacentini, Federico; Omarini, Claudia; Ficarra, G; Balduzzi, Sara; Dominici, Massimo; Conte, Pierfranco; Guarneri, Valentina |